Skip to main content

Table 1 Patient characteristics (n = 70)

From: Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial

Age at baseline

Mean (SD)

73.4 (6.3)

ISUP Grade Group (n %)

1

1 (1.4)

2

21 (30.0)

3

18 (25.7)

4

9 (12.9)

5

21 (30.0)

Clinical stage

T1

17 (24.3)

T2

29 (41.4)

T3

21 (30.0)

Missing

3 (4.3)

ADT

Nil

34 (48.6)

Neo-adjuvant

26 (37.1)

Adjuvant

10 (14.3)

PSA at enrolment (ng/mL)

Median (25th to 75th percentile)

10.2 (6.2–17.1)

  1. Data are presented as no. (%) unless otherwise indicated
  2. ADT androgen deprivation therapy, ISUP International Society of Urological Pathology, PSA prostate specific antigen, SD standard deviation